Massimo Iavarone
@massimoiava.bsky.social
Husband since 1995, father of 3, hepatologist caring for patients and research. Posts are mine. he/his
Reposted by Massimo Iavarone
The authors in today’s #readoftheweek📚 discuss how patients with #ALD and #MASLD are underrepresented in #HCC risk model development studies.
Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...
#LiverSky @jhepatology.bsky.social
Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...
#LiverSky @jhepatology.bsky.social
January 22, 2025 at 2:01 PM
The authors in today’s #readoftheweek📚 discuss how patients with #ALD and #MASLD are underrepresented in #HCC risk model development studies.
Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...
#LiverSky @jhepatology.bsky.social
Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...
#LiverSky @jhepatology.bsky.social
Reposted by Massimo Iavarone
🆕 Treatment of refractory #ascites: TIPS, tunneled peritoneal catheter (PeCa), or ascites pump?
🥇 TIPS: lowest incidence of complications
🦠 PeCa: peritonitis & device explantations 📈
👥 Sarah Schütte et al in Hepatology Communications
🔗 bit.ly/42k8too
#liversky #medsky #cirrhosis
🥇 TIPS: lowest incidence of complications
🦠 PeCa: peritonitis & device explantations 📈
👥 Sarah Schütte et al in Hepatology Communications
🔗 bit.ly/42k8too
#liversky #medsky #cirrhosis
January 21, 2025 at 11:06 AM
🆕 Treatment of refractory #ascites: TIPS, tunneled peritoneal catheter (PeCa), or ascites pump?
🥇 TIPS: lowest incidence of complications
🦠 PeCa: peritonitis & device explantations 📈
👥 Sarah Schütte et al in Hepatology Communications
🔗 bit.ly/42k8too
#liversky #medsky #cirrhosis
🥇 TIPS: lowest incidence of complications
🦠 PeCa: peritonitis & device explantations 📈
👥 Sarah Schütte et al in Hepatology Communications
🔗 bit.ly/42k8too
#liversky #medsky #cirrhosis
#atezolizumab plus #bevacizumab prior #liver #transplantation for #HCC - JHEP Reports www.jhep-reports.eu/article/S258...
🔹 82% downstaged to Milan criteria
🔹 94% radiological response (59% CR)
🔹 88% pathological response
🔹 No graft loss or severe rejection
A potential game-changer!
🔹 82% downstaged to Milan criteria
🔹 94% radiological response (59% CR)
🔹 88% pathological response
🔹 No graft loss or severe rejection
A potential game-changer!
Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
The combination of atezolizumab and bevacizumab offers a novel approach to immunomodulation,
showing efficacy as a primary treatment in advanced hepatocellular carcinoma (HCC).
Concerns about graft sa...
www.jhep-reports.eu
January 22, 2025 at 5:46 PM
#atezolizumab plus #bevacizumab prior #liver #transplantation for #HCC - JHEP Reports www.jhep-reports.eu/article/S258...
🔹 82% downstaged to Milan criteria
🔹 94% radiological response (59% CR)
🔹 88% pathological response
🔹 No graft loss or severe rejection
A potential game-changer!
🔹 82% downstaged to Milan criteria
🔹 94% radiological response (59% CR)
🔹 88% pathological response
🔹 No graft loss or severe rejection
A potential game-changer!